Description: AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines. The company's lead compound is the Masitinib, a tyrosine kinase inhibitor that is in Phase III trials for the treatment of oncology, inflammatory, multiple sclerosis, Alzheimer's, and amyotrophic lateral sclerosis diseases. It also develops other compounds, such as KIT816 for the treatment of aggressive mastocytosis, seminoma, and acute myeloid leukemia; and Syk for treating rheumatoid arthritis/B-cell lymphoma. In addition, AB Science S.A. offers Masitinib for the treatment of oncology and inflammatory diseases for dogs and cats. The company markets its Masitinib under the Masivet brand in Europe; and Kinavet brand in the United States. It serves hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.
Home Page: www.ab-science.com
3, Avenue George V
Paris,
75008
France
Phone:
33 1 47 20 00 14
Officers
| Name | Title |
|---|---|
| Mr. Alain Moussy MBA | Co-Founder, Chairman, Pres, CEO, MD & Scientific Director |
| Mr. Laurent Guy MBA | Chief Financial Officer |
| Mr. Christian FASSOTTE | Global Chief Medical Officer |
| Mr. Alexis BERNARD | Head of Veterinary Sales |
| Mr. Harshad KULKARNI | Head of Statistics |
| Dr. Yves Grumser M.D. | Head of Clinical Safety & Pharmacovigilance |
| Dr. Albert Ahn D.V.M. | Pres of USA Operations |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 328.8624 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 100 |